Vol 7: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Report as inadecuate



 Vol 7: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.


Vol 7: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 7: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
This article is from Journal of Hematology & Oncology, volume 7.AbstractBackground: Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy have a poor prognosis.
CD40 is expressed on multiple B-cell neoplasms including DLBCL and is a potential target for immunotherapy.
Dacetuzumab (SGN-40), a non-blocking,

Author: de Vos, Sven; Forero-Torres, Andres; Ansell, Stephen M; Kahl, Brad; Cheson, Bruce D; Bartlett, Nancy L; Furman, Richard R; Winter, Jane N; Kaplan, Hen

Source: https://archive.org/



DOWNLOAD PDF




Related documents